Panajin Files Patent Application for PNA-Based Selective Target Amplification Technology

[Asia Economy Reporter Lee Gwan-joo] Panagen announced on the 22nd that it has filed a patent application for 'AssiProbe™,' a selective target gene amplification technology based on PNA (peptide nucleic acid).

The AssiProbe technology developed by Panagen is a core technology that selectively amplifies only the target gene mutations using PNA. The company explained that it not only makes it easier and more accurate to confirm the presence of the desired genotype among various gene mutations, but also significantly improves sensitivity and facilitates multiplex detection.

Panagen expects a synergistic effect by combining the AssiProbe technology with its non-target amplification suppression technology, 'PNAClamp™.' Additionally, it anticipates expanding the applicability of PNA materials in molecular diagnostics by providing further successful examples of PNA material utilization.

A Panagen official stated, “The success in developing the AssiProbe technology is significant in that it secures an essential core technology for improving the performance of molecular diagnostic products,” and added, “It will also contribute to increasing sales of our diagnostic products in the high-growth in vitro molecular diagnostics market, which has an average annual growth rate of 6.7%, serving as a stepping stone to enhance our global market share.”

This content was produced with the assistance of AI translation services.